Save on Elbasvir/Grazoprevir with Coupons, Discounts & Savings Programs

Elbasvir/Grazoprevir is available as an oral tablet that contains 50 mg elbasvir and 100 mg grazoprevir.

Elbasvir/Grazoprevir is an antiviral combo and is used to treat hepatitis C infection genotype 1 and 4.

Elbasvir/Grazoprevir contains 2 antiviral medications that work together to stop the hepatitis C virus from making copies of itself in the body.

Elbasvir/Grazoprevir is typically dosed at 1 tablet once a day with or without food.

Elbasvir/Grazoprevir is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication in the following:

• Patients with moderate or severe hepatic impairment (Child-Pugh B or C)
• OATP1B1/3 inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations, strong CYP3A inducers,
  and efavirenz
• If Elbasvir/Grazoprevir is administered with ribavirin, the contraindications to ribavirin also apply

Common side effects of Elbasvir/Grazoprevir:

• Fatigue
• Headache

Serious side effects are rare with Elbasvir/Grazoprevir.

The following medications may interact with Elbasvir/Grazoprevir:

• Co-administration of Elbasvir/Grazoprevir with moderate CYP3A inducers is not recommended as they may decrease the plasma concentration of Elbasvir/Grazoprevir
• Co-administration of Elbasvir/Grazoprevir with certain strong CYP3A inhibitors is not recommended as they may increase the plasma concentration of Elbasvir/Grazoprevir
• Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant
• laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary
• Consult the full prescribing information prior to and during treatment for potential drug interactions

Various FDA-approved generic manufacturers

No adequate human data are available to establish whether or not Elbasvir/Grazoprevir poses a risk to pregnancy outcomes.
If Elbasvir/Grazoprevir is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Females should avoid pregnancy during treatment and within 6 months of stopping ribavirin and to notify their healthcare provider immediately in the event of a pregnancy.

• Zepatier